Global Dyslexia Treatment Market – Industry Trends and Forecast to 2030

Request for TOC Request for TOC Speak to Analyst Speak to Analyst Free Sample Report Free Sample Report Inquire Before Buying Inquire Before Buy Now Buy Now

Global Dyslexia Treatment Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Feb 2023
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Circumvent the Tariff challenges with an agile supply chain Consulting

Supply Chain Ecosystem Analysis now part of DBMR Reports

Global Dyslexia Treatment Market

Market Size in USD Billion

CAGR :  % Diagram

Bar chart comparing the Global Dyslexia Treatment Market size in 2022 - 4096.10 and 2030 - 6677.85, highlighting the projected market growth. USD 4,096.10 Billion USD 6,677.85 Billion 2022 2030
Diagram Forecast Period
2023 –2030
Diagram Market Size (Base Year)
USD 4,096.10 Billion
Diagram Market Size (Forecast Year)
USD 6,677.85 Billion
Diagram CAGR
%
Diagram Major Markets Players
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • GSK plc
  • Lupin
  • Lilly

Global Dyslexia Treatment Market, By Type (Double Deficit Dyslexia, Visual Dyslexia, Phonological Dyslexia and Others), Therapy Type (Occupational Therapy, Speech Therapy and Cognitive Behavioural Therapy), Drug Class (Antihistamine, Central Nervous Stimulant, Anti-Myoclonic and Others), Drugs (Cyclizine, Meclizine, Dimenhydrinate, Methylphenidate and Others), Route of Administration (Oral and Injectable), End Users (Psychiatric Institutions, Rehabilitation Centres, Home Care  and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others) – Industry Trends and Forecast to 2030.

Dyslexia Treatment Market

Dyslexia Treatment Market Analysis and Size

According to statistics, one in ten persons globally suffers from dyslexia. Between 25 and 40 percent of children who have dyslexia also have attention deficit hyperactivity disorder, while about 25 percent of children with ADHD also have dyslexia. According to "The Economic Impact of Dyslexia on California," a report released in July 2020 by the US-based Boston Consulting Group, dyslexia would cost California approximately $12 billion in 2020 and $1 trillion over the following 60 years. As a result, it is anticipated that within the forecast period, the particular diagnostic rate will grow as emerging economies become more aware of dyslexia. Increased application development efforts to cure dyslexia are also fuelling the market.

Data Bridge Market Research analyses that the dyslexia treatment market, which is USD 4,096.1 million in 2022, is expected to reach USD 6,677.85 million by 2030, at a CAGR of 6.3% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Dyslexia Treatment Market Scope and Segmentation      

Report Metric

Details

Forecast Period

2023 to 2030

Base Year

2022

Historic Years

2021 (Customizable to 2015 - 2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Type (Double Deficit Dyslexia, Visual Dyslexia, Phonological Dyslexia and Others), Therapy Type (Occupational Therapy, Speech Therapy and Cognitive Behavioural Therapy), Drug Class (Antihistamine, Central Nervous Stimulant, Anti-Myoclonic and Others), Drugs (Cyclizine, Meclizine, Dimenhydrinate, Methylphenidate and Others), Route of Administration (Oral and Injectable), End Users (Psychiatric Institutions, Rehabilitation Centres, Home Care  and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Teva Pharmaceutical Industries Ltd. (Israel), Takeda Pharmaceutical Company Limited (Japan), GSK plc (U.K.), Lupin (India), Lilly (U.S.), Sun Pharmaceutical Industries Ltd. (India), Novartis AG (Switzerland), Astrazeneca (U.K.), Pfizer Inc. (U.S.), Endo Pharmaceuticals Inc. (U.S.), Amneal Pharmaceuticals LLC (U.S.), Bionpharma (U.S.), ANI Pharmaceuticals, Inc. (U.S.), Viatris Inc. (U.S.), Breckenridge Pharmaceutical, Inc. (U.S.), Ironshore Pharmaceuticals Inc. (U.S.), Alkem Labs (India), Mallinckrodt (U.K.) and Alvogen (U.S.)

Market Opportunities

  • Rising in specific diagnostic rate is a promising opportunity

Market Definition

Dyslexia is having trouble remembering unfamiliar or challenging words, reading, and writing. People from many walks of life are affected by this neurological learning disease. Early intervention is possible for children with dyslexia through specialized teaching methods. Researchers are working hard to overcome these challenges because no two dyslexic youngsters display the same set of symptoms. Drugs and central nervous system stimulants are frequently recommended for dyslexia and ADHD even though there is no known treatment for either condition.

Dyslexia Treatment Market Dynamics

Drivers

  • Rising healthcare infrastructure will bolster the growth

The global market for dyslexia treatment is expanding due to rising healthcare infrastructure development spending and increased demand for disease-specific novel treatments. The rise in personal disposable income and the great unmet demand for this condition are additional indirect factors that create lucrative market expansion. Dyslexia is the most prevalent language-based learning issue, according to the Dyslexia Center of Utah. About 70–80 percent of those who struggle to read are dyslexic. One in five students, or 15-20% of the population, has a language-based learning issue. There is an almost equal prevalence of dyslexia in both sexes. Furthermore, 38% of all fourth-graders have "below basic" reading skills, according to the National Assessment of Educational Progress (NAEP).

  • Increase the need for dyslexia treatment will propel the market growth

The cost to society of the failure to master fundamental reading abilities throughout school years is also expected to increase the need for dyslexia treatment. As an illustration, in the UK, the expenditure per person up to the age of 37 is between US$6746 AND US$58,015.60 and between US$6746 throughout the life of individual. as a result, the usd value increases from US$267.14 million to US$3.37 billion.

Opportunities

  • Rising in specific diagnostic rate is a promising opportunity

Since emerging economies are expected to become more aware of dyslexia throughout the forecast period, the specific diagnostic rate is expected to increase. The market is also being fuelled by increased efforts to create applications to treat dyslexia. The specific diagnostic rate is predicted to rise because emerging economies are anticipated to become more aware of dyslexia during the forecast period.

Restraints/Challenges

  • Side-effects associated with dyslexia treatment

Having trouble in reading, even when reading aloud is one of the dyslexia symptoms and signs that affects teens and adults frequently. Writing and reading that takes a lot of effort. Spelled incorrectly refraining from reading-related activities, errors in pronunciation, difficulties in word retrieval, among others are the side effects of dyslexia treatment.

The development of vocabulary and background information may be hampered by secondary effects such as reading comprehension issues and a decreased reading pleasure. The ability and drive required to learn to read are there in a person with dyslexia, but they struggle with reading and writing.

This dyslexia treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the dyslexia treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Dyslexia Treatment Market Scope

The dyslexia treatment market is segmented on the basis of type, therapy type, drug class, drugs, route of administration, end users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Double Deficit Dyslexia
  • Visual Dyslexia
  • Phonological Dyslexia
  • Others

 Therapy Type

  • Occupational Therapy
  • Speech Therapy
  • Cognitive Behavioural Therapy

Drug Class

  • Antihistamine
  • Central Nervous Stimulant
  • Anti-Myoclonic
  • Others

 Drugs

  • Cyclizine
  • Meclizine
  • Dimenhydrinate
  • Methylphenidate
  • Others

 Route of Administration

  • Oral
  • Injectable

 End Users

  • Psychiatric Institutions
  • Rehabilitation Centres
  • Home Care 
  • Others

 Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Dyslexia Treatment Market Regional Analysis/Insights

The dyslexia treatment market is analysed and market size insights and trends are provided by country, type, therapy type, drug class, drugs, route of administration, end users and distribution channel as referenced above.

The countries covered in the dyslexia treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the dyslexia treatment market due to the increased costs for developing research and development capabilities, high prevalence of dyslexia and also due to the availability of high-tech devices. Additionally, rising public awareness and an increase in the number of students enrolled in special education programmes contribute to the expansion of the region in this market.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 due to rising healthcare infrastructure development costs, an increase in the prevalence of neurological illnesses and rising personal disposable income.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Dyslexia Treatment Market Share Analysis

The dyslexia treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to dyslexia treatment market.

Some of the major players operating in the dyslexia treatment market are:

  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Takeda Pharmaceutical Company Limited (Japan)
  • GSK plc (U.K.)
  • Lupin (India)
  • Lilly (U.S.)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Novartis AG (Switzerland)
  • Astrazeneca (U.K.)
  • Pfizer Inc. (U.S.)
  • Endo Pharmaceuticals Inc. (U.S.)
  • Amneal Pharmaceuticals LLC (U.S.)
  • Bionpharma (U.S.)
  • ANI Pharmaceuticals, Inc. (U.S.)
  • Viatris Inc. (U.S.)
  • Breckenridge Pharmaceutical, Inc. (U.S.)
  • Ironshore Pharmaceuticals Inc. (U.S.)
  • Alkem Labs (India)
  • Mallinckrodt (U.K.)
  • Alvogen (U.S.)


SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL DYSLEXIA TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATION

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 KEY TAKEAWAYS

2.2 ARRIVING AT THE GLOBAL DYSLEXIA TREATMENT MARKET SIZE

2.2.1 VENDOR POSITIONING GRID

2.2.2 TECHNOLOGY LIFE LINE CURVE

2.2.3 TRIPOD DATA VALIDATION MODEL

2.2.4 MARKET GUIDE

2.2.5 MULTIVARIATE MODELLING

2.2.6 TOP TO BOTTOM ANALYSIS

2.2.7 CHALLENGE MATRIX

2.2.8 APPLICATION COVERAGE GRID

2.2.9 STANDARDS OF MEASUREMENT

2.2.10 VENDOR SHARE ANALYSIS

2.2.11 EPIDEMIOLOGY MODELING

2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS

2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES

2.3 GLOBAL DYSLEXIA TREATMENT MARKET: RESEARCH SNAPSHOT

2.4 ASSUMPTIONS

3 MARKET OVERVIEW

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 CHALLENGES

4 EXECUTIVE SUMMARY

5 PREMIUM INSIGHTS

5.1 PESTEL ANALYSIS

5.2 PORTER’S FIVE FORCES MODEL

6 EPIDEMIOLOGY

7 INDUSTRY INSIGHTS

8 PREMIUM INSIGHTS

9 REGULATORY SCENARIO

10 PIPELINE ANALYSIS

10.1 OVERVIEW

10.2 LATE STAGE PRODUCTS (PHASE III) CANDIDATES

10.3 MID-STAGE PRODUCTS (PHASE II) CANDIDATES

10.4 EARLY-STAGE PRODUCT (PHASE I) CANDIDATES

10.5 PRE-CLINICAL (DISCOVERY STAGE) CANDIDATES

11 GLOBAL DYSLEXIA TREATMENT MARKET, BY TYPE

11.1 OVERVIEW

11.2 DOUBLE DEFICIT DYSLEXIA

11.3 VISUAL DYSLEXIA

11.4 PHONOLOGICAL DYSLEXIA

11.5 RAPID NAMING DYSLEXIA

11.6 SURFACE DYSLEXIA

11.7 OTHERS

12 GLOBAL DYSLEXIA TREATMENT MARKET, BY TREATMENT

12.1 OVERVIEW

12.2 THERAPY

12.2.1 OCCUPATIONAL THERAPY

12.2.2 SPEECH THERAPY

12.2.3 COGNITIVE BEHAVIOURAL THERAPY

12.2.4 VISUAL & AUDITORY THERAPIES

12.2.5 OTHERS

12.3 DRUGS

12.3.1 ANTIHISTAMINE

12.3.1.1. CYCLIZINE

12.3.1.2. MECLIZINE

12.3.1.3. DIMENHYDRINATE

12.3.1.4. OTHERS

12.3.2 CENTRAL NERVOUS STIMULANT

12.3.2.1. METHYLPHENIDATE

12.3.2.2. DEXTROAMPHETAMINE

12.3.2.3. DOPAMINE

12.3.2.4. OTHERS

12.3.3 ANTI-MYOCLONIC

12.3.4 PIRACETAM

12.3.5 ATOMOXETINE

12.3.6 OTHERS

12.4 OTHERS

13 GLOBAL DYSLEXIA TREATMENT MARKET, BY DRUG TYPE

13.1 OVERVIEW

13.2 BRANDED

13.2.1 RITALIN

13.2.2 DEXEDRINE

13.2.3 ADDERALL

13.2.4 STRATTERA

13.2.5 PIRAMAX

13.2.6 OTHERS

13.3 GENERIC

14 GLOBAL DYSLEXIA TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

14.1 OVERVIEW

14.2 ORAL

14.3 PARENTERAL

14.3.1 INTRAVENOUS

14.3.2 SUBCUTANEOUS

14.3.3 OTHERS

14.4 OTHERS

15 GLOBAL DYSLEXIA TREATMENT MARKET, BY AGE GROUP

15.1 OVERVIEW

15.2 CHILDREN

15.3 ADULTS

15.3.1 MALE

15.3.2 FEMALE

16 GLOBAL DYSLEXIA TREATMENT MARKET, BY END USER

16.1 OVERVIEW

16.2 HOSPITALS

16.3 CLINICS

16.4 SPECIALTY CENTRES

16.5 PSYCHIATRIC INSTITUTIONS

16.6 REHABILITATION CENTERS

16.7 HOMECARE

16.8 OTHERS

17 GLOBAL DYSLEXIA TREATMENT MARKET, BY DISTRIBUTION CHANNEL

17.1 OVERVIEW

17.2 HOSPITAL PHARMACIES

17.3 RETAIL PHARMACIES

17.4 ONLINE PHARMACIES

17.5 OTHERS

18 GLOBAL DYSLEXIA TREATMENT MARKET, SWOT AND DBMR ANALYSIS

19 GLOBAL DYSLEXIA TREATMENT MARKET, COMPANY LANDSCAPE

19.1 COMPANY SHARE ANALYSIS: GLOBAL

19.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

19.3 COMPANY SHARE ANALYSIS: EUROPE

19.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

19.5 MERGERS & ACQUISITIONS

19.6 NEW PRODUCT DEVELOPMENT & APPROVALS

19.7 EXPANSIONS

19.8 REGULATORY CHANGES

19.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS

20 GLOBAL DYSLEXIA TREATMENT MARKET, BY REGION

GLOBAL DYSLEXIA TREATMENT MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)

20.1 NORTH AMERICA

20.1.1 U.S.

20.1.2 CANADA

20.1.3 MEXICO

20.2 EUROPE

20.2.1 GERMANY

20.2.2 U.K.

20.2.3 ITALY

20.2.4 FRANCE

20.2.5 SPAIN

20.2.6 RUSSIA

20.2.7 SWITZERLAND

20.2.8 TURKEY

20.2.9 BELGIUM

20.2.10 NETHERLANDS

20.2.11 DENMARK

20.2.12 SWEDEN

20.2.13 POLAND

20.2.14 NORWAY

20.2.15 FINLAND

20.2.16 REST OF EUROPE

20.3 ASIA-PACIFIC

20.3.1 JAPAN

20.3.2 CHINA

20.3.3 SOUTH KOREA

20.3.4 INDIA

20.3.5 SINGAPORE

20.3.6 THAILAND

20.3.7 INDONESIA

20.3.8 MALAYSIA

20.3.9 PHILIPPINES

20.3.10 AUSTRALIA

20.3.11 NEW ZEALAND

20.3.12 VIETNAM

20.3.13 TAIWAN

20.3.14 REST OF ASIA-PACIFIC

20.4 SOUTH AMERICA

20.4.1 BRAZIL

20.4.2 ARGENTINA

20.4.3 REST OF SOUTH AMERICA

20.5 MIDDLE EAST AND AFRICA

20.5.1 SOUTH AFRICA

20.5.2 EGYPT

20.5.3 BAHRAIN

20.5.4 UNITED ARAB EMIRATES

20.5.5 KUWAIT

20.5.6 OMAN

20.5.7 QATAR

20.5.8 SAUDI ARABIA

20.5.9 REST OF MEA

21 GLOBAL DYSLEXIA TREATMENT MARKET, COMPANY PROFILE

21.1 NOVARTIS AG

21.1.1 COMPANY OVERVIEW

21.1.2 REVENUE ANALYSIS

21.1.3 GEOGRAPHIC PRESENCE

21.1.4 PRODUCT PORTFOLIO

21.1.5 RECENT DEVELOPMENTS

21.2 TRIS PHARMA, INC.

21.2.1 COMPANY OVERVIEW

21.2.2 REVENUE ANALYSIS

21.2.3 GEOGRAPHIC PRESENCE

21.2.4 PRODUCT PORTFOLIO

21.2.5 RECENT DEVELOPMENTS

21.3 TEVA PHARMACEUTICAL INDUSTRIES LTD

21.3.1 COMPANY OVERVIEW

21.3.2 REVENUE ANALYSIS

21.3.3 GEOGRAPHIC PRESENCE

21.3.4 PRODUCT PORTFOLIO

21.3.5 RECENT DEVELOPMENTS

21.4 SUN PHARMACEUTICAL INDUSTRIES LTD

21.4.1 COMPANY OVERVIEW

21.4.2 REVENUE ANALYSIS

21.4.3 GEOGRAPHIC PRESENCE

21.4.4 PRODUCT PORTFOLIO

21.4.5 RECENT DEVELOPMENTS

21.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED

21.5.1 COMPANY OVERVIEW

21.5.2 REVENUE ANALYSIS

21.5.3 GEOGRAPHIC PRESENCE

21.5.4 PRODUCT PORTFOLIO

21.5.5 RECENT DEVELOPMENTS

21.6 MALLINCKRODT

21.6.1 COMPANY OVERVIEW

21.6.2 REVENUE ANALYSIS

21.6.3 GEOGRAPHIC PRESENCE

21.6.4 PRODUCT PORTFOLIO

21.6.5 RECENT DEVELOPMENTS

21.7 MAYNE PHARMA

21.7.1 COMPANY OVERVIEW

21.7.2 REVENUE ANALYSIS

21.7.3 GEOGRAPHIC PRESENCE

21.7.4 PRODUCT PORTFOLIO

21.7.5 RECENT DEVELOPMENTS

21.8 NOVEL LABORATORIES, INC.

21.8.1 COMPANY OVERVIEW

21.8.2 REVENUE ANALYSIS

21.8.3 GEOGRAPHIC PRESENCE

21.8.4 PRODUCT PORTFOLIO

21.8.5 RECENT DEVELOPMENTS

21.9 ENDO PHARMACEUTICALS, INC.

21.9.1 COMPANY OVERVIEW

21.9.2 REVENUE ANALYSIS

21.9.3 GEOGRAPHIC PRESENCE

21.9.4 PRODUCT PORTFOLIO

21.9.5 RECENT DEVELOPMENTS

21.1 AMNEAL PHARMACEUTICALS LLC

21.10.1 COMPANY OVERVIEW

21.10.2 REVENUE ANALYSIS

21.10.3 GEOGRAPHIC PRESENCE

21.10.4 PRODUCT PORTFOLIO

21.10.5 RECENT DEVELOPMENTS

21.11 ALVOGEN

21.11.1 COMPANY OVERVIEW

21.11.2 REVENUE ANALYSIS

21.11.3 GEOGRAPHIC PRESENCE

21.11.4 PRODUCT PORTFOLIO

21.11.5 RECENT DEVELOPMENTS

21.12 BIONPHARMA

21.12.1 COMPANY OVERVIEW

21.12.2 REVENUE ANALYSIS

21.12.3 GEOGRAPHIC PRESENCE

21.12.4 PRODUCT PORTFOLIO

21.12.5 RECENT DEVELOPMENTS

21.13 ANI PHARMACEUTICALS, INC.

21.13.1 COMPANY OVERVIEW

21.13.2 REVENUE ANALYSIS

21.13.3 GEOGRAPHIC PRESENCE

21.13.4 PRODUCT PORTFOLIO

21.13.5 RECENT DEVELOPMENTS

21.14 ASCENT PHARMACEUTICALS, INC.

21.14.1 COMPANY OVERVIEW

21.14.2 REVENUE ANALYSIS

21.14.3 GEOGRAPHIC PRESENCE

21.14.4 PRODUCT PORTFOLIO

21.14.5 RECENT DEVELOPMENTS

21.15 BRECKENRIDGE PHARMACEUTICAL, INC.

21.15.1 COMPANY OVERVIEW

21.15.2 REVENUE ANALYSIS

21.15.3 GEOGRAPHIC PRESENCE

21.15.4 PRODUCT PORTFOLIO

21.15.5 RECENT DEVELOPMENTS

21.16 IRONSHORE PHARMACEUTICALS, INC.

21.16.1 COMPANY OVERVIEW

21.16.2 REVENUE ANALYSIS

21.16.3 GEOGRAPHIC PRESENCE

21.16.4 PRODUCT PORTFOLIO

21.16.5 RECENT DEVELOPMENTS

21.17 ALKEM LABS

21.17.1 COMPANY OVERVIEW

21.17.2 REVENUE ANALYSIS

21.17.3 GEOGRAPHIC PRESENCE

21.17.4 PRODUCT PORTFOLIO

21.17.5 RECENT DEVELOPMENTS

21.18 FRESENIUS KABI AG

21.18.1 COMPANY OVERVIEW

21.18.2 REVENUE ANALYSIS

21.18.3 GEOGRAPHIC PRESENCE

21.18.4 PRODUCT PORTFOLIO

21.18.5 RECENT DEVELOPMENTS

21.19 GLAXOSMITHKLINE PLC

21.19.1 COMPANY OVERVIEW

21.19.2 REVENUE ANALYSIS

21.19.3 GEOGRAPHIC PRESENCE

21.19.4 PRODUCT PORTFOLIO

21.19.5 RECENT DEVELOPMENTS

21.2 LUPIN PHARMACEUTICALS

21.20.1 COMPANY OVERVIEW

21.20.2 REVENUE ANALYSIS

21.20.3 GEOGRAPHIC PRESENCE

21.20.4 PRODUCT PORTFOLIO

21.20.5 RECENT DEVELOPMENTS

21.21 ELI LILLY AND COMPANY

21.21.1 COMPANY OVERVIEW

21.21.2 REVENUE ANALYSIS

21.21.3 GEOGRAPHIC PRESENCE

21.21.4 PRODUCT PORTFOLIO

21.21.5 RECENT DEVELOPMENTS

21.22 ASTRAZENECA

21.22.1 COMPANY OVERVIEW

21.22.2 REVENUE ANALYSIS

21.22.3 GEOGRAPHIC PRESENCE

21.22.4 PRODUCT PORTFOLIO

21.22.5 RECENT DEVELOPMENTS

21.23 PFIZER INC

21.23.1 COMPANY OVERVIEW

21.23.2 REVENUE ANALYSIS

21.23.3 GEOGRAPHIC PRESENCE

21.23.4 PRODUCT PORTFOLIO

21.23.5 RECENT DEVELOPMENTS

21.24 THE HIMMEL GROUP

21.24.1 COMPANY OVERVIEW

21.24.2 REVENUE ANALYSIS

21.24.3 GEOGRAPHIC PRESENCE

21.24.4 PRODUCT PORTFOLIO

21.24.5 RECENT DEVELOPMENTS

21.25 RPG LIFE SCIENCES LTD.

21.25.1 COMPANY OVERVIEW

21.25.2 REVENUE ANALYSIS

21.25.3 GEOGRAPHIC PRESENCE

21.25.4 PRODUCT PORTFOLIO

21.25.5 RECENT DEVELOPMENTS

21.26 WALLACE PHARMACEUTICAL LTD.

21.26.1 COMPANY OVERVIEW

21.26.2 REVENUE ANALYSIS

21.26.3 GEOGRAPHIC PRESENCE

21.26.4 PRODUCT PORTFOLIO

21.26.5 RECENT DEVELOPMENTS

21.27 APOTEX CORPORATION

21.27.1 COMPANY OVERVIEW

21.27.2 REVENUE ANALYSIS

21.27.3 GEOGRAPHIC PRESENCE

21.27.4 PRODUCT PORTFOLIO

21.27.5 RECENT DEVELOPMENTS

22 RELATED REPORTS

23 CONCLUSION

24 QUESTIONNAIRE

25 ABOUT DATA BRIDGE MARKET RESEARCH

View Detailed Information Right Arrow

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Frequently Asked Questions

The Dyslexia Treatment Market is projected to grow at a CAGR of 6.3% during the forecast period by 2030.
The future market value of the Dyslexia Treatment Market is expected to reach USD 6,677.85 million by 2030.
The major players in the Dyslexia Treatment Market are Teva Pharmaceutical Industries Ltd. (Israel), Takeda Pharmaceutical Company Limited (Japan), GSK plc (U.K.), Lupin (India), Lilly (U.S.), Sun Pharmaceutical Industries Ltd. (India), Novartis AG (Switzerland), etc.
The countries covered in the Dyslexia Treatment Market are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, etc.

Industry Related Reports

Testimonial